Natixis Puma Biotechnology, Inc. Transaction History

Natixis

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 13, 2019	BUY	$12.3 - $35.76 $339,664 - $987,512	27,615 New	27,615 $351,000
Q3 2018 Nov 14, 2018	SELL	$41.2 - $59.85 $392,718 - $570,490	-9,532 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$48.3 - $68.25 $62,306 - $88,042	-1,290 Reduced 11.92%	9,532 $564,000
Q1 2018 May 15, 2018	BUY	$59.7 - $99.25 $97,370 - $161,876	1,631 Added 17.75%	10,822 $736,000
Q4 2017 Feb 14, 2018	BUY	$93.85 - $132.45 $257,430 - $363,310	2,743 Added 42.54%	9,191 $909,000
Q3 2017 Nov 14, 2017	BUY	$72.0 - $119.75 $464,256 - $772,148	6,448	6,448 $772,000

110

28.3M

27.9K

3.4K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $155M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.